Curon Secca Incontinence System One-Year Data Include 80% Success Rate
This article was originally published in The Gray Sheet
Executive Summary
One-year follow-up data on ten patients treated with Curon Medical's Secca radiofrequency system for treatment of fecal incontinence, slated for release in June, include an 80% success rate, Curon says.
You may also be interested in...
Curon’s Secca System For Fecal Incontinence Receives 510(k) Clearance
Curon Medical's 12 sales reps will market the Secca system for the treatment of fecal incontinence. FDA 510(k) clearance was announced March 25
Curon’s Secca System For Fecal Incontinence Receives 510(k) Clearance
Curon Medical's 12 sales reps will market the Secca system for the treatment of fecal incontinence. FDA 510(k) clearance was announced March 25
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.